Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations

NCT06080165 | Withdrawn Phase 1 DMC FDA Drug

• 1 other identifier: IRB-72157
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 3

Brief Summary

The goal of this study is to examine the safety and treatment effects of sirolimus for targeting social communication deficits in people with genetic disorders associated with PTEN germline mutations, which are often referred to as PTEN Harmartoma Tumor Syndrome (PHTS). The mechanism of sirolimus in the body has shown promise for helping to improve social communication skills in case reports of people with PHTS. Everolimus, a closely related compound, also showed benefits in social communication skills in a previous pilot trial in people with PHTS. This is a 6 month double-blind trial followed by at 6 month open label extension trial.

Conditions

PTEN Gene Mutation; PTEN Hamartoma Tumor Syndrome; PTEN Hamartoma Syndrome

Keywords

Sirolimus; Rapamune

Outcome Measures

Primary Outcomes (1)

• Change from baseline in parent rated Social Responsiveness Scale, Second Edition Total Scores (SRS-2) total scores during treatment.

  Month 1, Month 2, Month 3, Month 4, Month 5, Month 6

Secondary Outcomes (2)

• Clinical Global Impression Improvement (CGI-I) Scale changes during treatment.

  Month 1, Month 2, Month 3, Month 4, Month 5, Month 6

• Change from baseline on parent rated Stanford Social Dimensions Scale (SSDS)

  Month 1, Month 2, Month 3, Month 4, Month 5, Month 6

Other Outcomes (12)

• Change from baseline on Brief Observation of Social Communication Change (BOSCC)

  Month 6

• Change from baseline on Neurobehavioral Evaluation Tool (NET) Social Communication and Interaction subscale

  Month 3, Month 6

• Change from baseline on the Reading the Mind in the Eyes Test (RMET)

  Month 6

Study Arms (2)

Sirolimus

EXPERIMENTAL

Participants that are 5 to 12.99 years old will start at 1 mg/m2/dose. Participants that are 13 to 45.99 years old and \< 39.99 kg in weight will also start on 1 mg/day. Participants that are 13 to 45.99 years old and \> 40 kg in weight will start on 2 mg/day. The target blood level will be 5-15 ng/ml with dose adjustment based on sirolimus levels obtained every 2 to 3 weeks after every dose change.

Drug: Sirolimus

Placebo

PLACEBO COMPARATOR

matching placebo

Drug: Placebo

Interventions

Sirolimus DRUG

Experimental: Sirolimus Participants that are 5 to 12.99 years old will start at 1 mg/m2/dose. Participants that are 13 to 45.99 years old and \< 39.99 kg in weight will also start on 1 mg/day. Participants that are 13 to 45.99 years old and \> 40 kg in weight will start on 2 mg/day. The target blood level will be 5-15 ng/ml with dose adjustment based on clinical labs of sirolimus levels. The target blood level will be 5-15 ng/ml with dose adjustment based on sirolimus levels obtained every 2 to 3 weeks after every dose change.

Also known as: Rapamune

Sirolimus

Placebo DRUG

matching placebo

Placebo

Eligibility Criteria

• Age: 5 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Male or female outpatients between 5.00 and 45.99 years of age
• PHTS confirmed by genetic testing;
• Fluent in English
• at least moderate severity of social skill deficits based on a social responsiveness scale t score ≥ 60
• Stable psychotropic and anti-epileptic medications for at least 4 weeks with the exception of fluoxetine which should be stable for at least 8 weeks
• Adequate Liver function (SGOT, SGPT, TBili, Alk Phos all\<3x normal); HCT\>27%; WBC \> 3.0, ANC \>1,500, and platelets \>100,000
• adequate renal function with a GFR ≥ 50 ml/min/m2 as determined by the Schwartz Formula for children and MDRD for adults (www.nkdep.nih.gov/professionals/gfr\_calculators/index)
• Negative urine pregnancy test for females and no plans to become pregnant or conceive a child while participating in the study. The effects of mTOR inhibitors on the developing fetus at the doses used in this study are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of the study. Because of the possibility of drug interactions and the potential effect of female hormones on the growth of kidney angiomyolipomas and lymphangioleiomyomatosis, estrogen-containing oral contraceptives are not recommended in women enrolled in this study, so an effective non-estrogen or barrier method of contraception must be used.
• Medically stable with no active medical problems such as unstable seizures or cardiovascular disease or cancer that is not in remission as evidenced by medical history; -No anticipated changes in frequency and intensity of existing interventions such as behavioral and developmental treatments, in home services, or speech therapy;
• No planned changes in school placement in children and adolescents;
• Availability of reliable transportation to attend clinic visits;
• availability of a trustworthy informant who interacts with subject on a regular basis;
• Ability to participate in the testing procedures to the extent that valid standard scores and biological samples can be obtained.

You may not qualify if:

• Participants will be excluded if one of the following is met:
• Significant medical illness, such as endocrinopathies, cardiovascular disease, or severe chronic malnutrition;
• Pregnancy, planned pregnancy, or unwillingness to use adequate contraception;
• Planned changes to concomitant medications;
• Concomitant therapy, or prior use within 3 months of the baseline visit, with an agent with known or possible anti-mTOR activity or concomitant therapy with strong inhibitors (e.g., cyclosporine and ketoconazole) or inducers of CYP3A;
• Active infection at time of enrollment;
• Participation in a clinical trial in the 30 days prior to study entry;
• Major surgery, radiation therapy or stereotactic radio-surgery within previous 4 weeks at time of enrollment; and
• Neurosurgery within prior 6 months at time of enrollment.

Sponsors & Collaborators

• Stanford University: lead

Study Sites (3)

Stanford University

Stanford, California, 94305, United States

Location

Boston Children's Hospital

Boston, Massachusetts, 02115, United States

Location

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location

MeSH Terms

Conditions

Hamartoma Syndrome, Multiple

Interventions

Sirolimus

Condition Hierarchy (Ancestors)

Hamartoma; Neoplasms; Neoplasms, Multiple Primary; Neoplastic Syndromes, Hereditary; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Macrolides; Lactones; Organic Chemicals

Study Officials

• Antonio Hardan, MD

  Stanford University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Double-Blind
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: September 29, 2023
• First Posted: October 12, 2023
• Study Start: July 1, 2024
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): June 1, 2028
• Last Updated: July 10, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will share
• Time Frame: shared twice per year

Locations

US (3)